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Nonhepatosplenic/noncutaneous cδ peripheral T-cell lymphoma (NHNCcδ PTCL) represents a miscellaneous group of unrelated
T-cell lymphomas of which only isolated cases have been reported. We describe two cases of transformation from T-lymphoblastic
leukemia/lymphoma to NHNCcδ PTCL. Transformation into more aggressive disease is a rare event in T-cell lineage-derived
hematologic malignancies compared to B-cell neoplasms. Nevertheless, both of our cases involved relapse as PTCL manifested
with skin involvement and an overt shift from blastic morphology to large granular leukemia-like mature T cells. Among other
notable molecular characteristics, expression of immature markers such as TdT was lost in both cases. Based on cytogenetics,
phenotype, and morphology, both patients represent a novel phenomenon of clonal transformation from T-ALL to PTCL which
has rarely been reported in the literature. Such transformation may carry important diagnostic and biological implications.

1. Introduction
Peripheral T-cell lymphomas (PTCLs) comprise a heterogeneous group of indolent and aggressive T-cell lymphomas
that confer a variable prognosis [1]. T-cell receptor gammadelta (TCRcδ) PTCLs are characterized based on their expression of cδ glycoproteins within the TCR complex rather
than more common alpha-beta (αβ) glycoproteins identiﬁed
in normal T-cells and in most T-cell neoplasms [2]. cδ T-cells
are subdivided into Vδ1 and Vδ2 subtypes and have demonstrated capacity for cytotoxicity, memory, and antigen
presentation [3]. Mature cδ PTCLs have no clear etiology to
date and can be divided into three categories based on location: hepatosplenic (HSTLcδ), cutaneous (PCTCLcδ), and
nonhepatosplenic/noncutaneous (NHNCcδ PTCL). HSTLcδ
and PCTCLcδ both carry a similarly dismal prognosis [4].
NHNCcδ PTCL represents a miscellaneous group of
unrelated T-cell lymphomas of which only isolated cases

have been reported; thus, characterization remains limited.
Reported sites of involvement include lymph nodes and
mucosal sites (nasopharynx and intestine), as well as the
larynx, thyroid, lung, breast, and testis [5–8]. NHNCcδ
subtypes of PTCLs generally behave more aggressively
compared to αβ counterparts with an exception of cδ variant
of T-cell large granular lymphocyte (LGL) leukemia [9].
No cytogenetics ﬁndings unique to NHNCcδ PTCL have
been reported [10]. i7q, if detected, is not speciﬁc to cδ
PCTLs [11]. Gene sequencing of cδ PCTLs has demonstrated
conservation of LGR4, C3AR1, and SCARF2 among all cδ
PTCLs [12]. Notably, the NHNCcδ PTCLs had CCL19,
MMP9, and UBD mutations, whereas HSTLcδ PCTLs did
not. These mutations were also strongly conserved in the αβ
PTCLs studied. Although there is evidence that some variants of cδ PTCLs respond in vitro to aurora kinase inhibitors, among all PTCLs, those with TCRcδ have the worst
prognoses [13–15].
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(a)
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Figure 1: Patient 1, bone marrow with T-cell ALL: (a) H&E core
biopsy, 500x; (b) aspirate cytology, 1000x.

As opposed to PTCL, the expression of cδ TCR is relatively
common in (up to 50%) in T-lymphoblastic leukemia/lymphoma
(T-ALL). Clinical features are similar to those that express
αβ TCR, and outcomes are comparable [8]. Here, we describe
a case of transformation from T-ALL to NHNCcδ PTCL.
Despite being rarely reported, we also report a second case of
PTCL arising in a patient with prior T-ALL. Such transformation may carry important diagnostic and biological
implications.

2. Case Presentations
2.1. Patient 1. Patient 1 is a 31-year-old gentleman diagnosed
with T-cell ALL after presenting with diﬀuse petechial rash,
cervical lymphadenopathy, abdominal pain, and a WBC of
121 K/μL with 40% blasts (Figure 1). Cytogenetics showed 46,
XY,add(13) (p11.2)[3]/46,XY[17]. No BCR/ABL was detected
by FISH; CSF was uninvolved. T-ALL was CD4+/CD8+,
CD2+, CD3+, CD5+ (dim), CD7+, and TdT (dim). He was
treated with vincristine, daunorubicin, pegylated L-asparaginase, and prednisolone achieving complete remission
(CR). He was referred for hematopoietic stem cell transplant
three months later which was delayed due to chemotherapy
complications. During this period, he received leucovorin
and glucarpidase. Prior to the transplant, a bone marrow
biopsy was negative, but revealed clonal TCR β and c gene
rearrangements. In addition, CSF showed numerous LGLlike cells. The patient developed high grade fever and over
one hundred erythematous plaques on his trunk, upper

Figure 2: Patient 1, erythematous patches and plaques of PTCL
distributed predominantly on torso and upper extremities.

extremities, and lower extremities (Figure 2). Skin biopsy
showed NHNCcδ PTCL (Figure 3) as did staging bone
marrow biopsy (Figure 4). The malignant cells demonstrated
mature chromatin, LGL-like morphology with prominent
azurophilic granules resembling those seen in patient 2’s
PTCL (see below). They coexpressed CD4, CD8, CD56,
cytotoxic markers, and c- TCR. TdT was negative. Molecular
studies of the PTCL demonstrated that both the T-ALL and
PTCL shared identical clonal TCR rearrangement peaks for
both TCR β and TCR c (Table 1).
Six months after initial CR, the patient was initiated on
ICE therapy and intra-Ommaya reservoir methotrexate (later
switched to intrathecal cytarabine). The skin lesions and CSF
involvement initially resolved; however, he developed fevers,
new generalized skin δc-PTCL, nodal/hepatic progression by
radiology, and CSF recurrence consistent with progressive
disease. Bone marrow transplant was deferred, and the patient
was admitted for hyper-CVAD chemotherapy. However, the
patient requested transfer despite the worsening condition.
Current clinical status is unknown.
2.2. Patient 2. Patient 2, deceased, was a 63-year-old Caucasian female with a past medical history signiﬁcant for stage
III invasive ductal carcinoma, ER/PR/HER2 negative, with 1 of
9 axillary lymph nodes positive for carcinoma, diagnosed at age
52. She underwent a left segmental mastectomy (lumpectomy)
procedure with axillary lymph node dissection, radiation
treatment, and 4 cycles of doxorubicin and cyclophosphamide
chemotherapy. Other medical problems included hypertension, hyperlipidemia, herpes zoster, childhood rheumatic fever,
menopause, and hypersensitivity pneumonitis.
She initially presented with a mediastinal mass, dyspnea,
and pericardial and recurrent right-sided pleural eﬀusions.
Biopsy of the mediastinal mass revealed blasts with cyCD3+,
TdT+, CD4+/8+, CD7+ (Figure 5). TCR gamma gene rearrangement studies demonstrated clonal gene rearrangements.
The peripheral blood and bone marrow were also involved.
She was treated with 18 cycles of hyper-CVAD followed
by POMP maintenance for 18 months and remained in
remission for nearly 4 years. Thereafter, she developed
dyspnea, and radiographic imaging showed several simultaneous masses, including a 4.7 × 4.0 cm right atrial mass
and a left ﬂank mass, in addition to pleural eﬀusions.
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(a)
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(c)

(d)
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Figure 3: Patient 1, right ﬂank skin with PTCL: (a) H&E, 100x; (b) H&E, 400x; (c) CD3, 100x; (d) TdT immunoperoxidase, 400x; (e) TCR
gamma, 200x.

(a)

(b)

(c)

(d)

Figure 4: Patient 1, bone marrow with PTCL: (a) H&E, 40x; (b, c) aspirate cytology, 1000x; (d) CD3, 100x.

No evidence of
malignancy

T-cell ALL

cδ PTCL

Cerebrospinal ﬂuid
120 days

Right iliac crest 124
days

T-cell ALL

Left iliac crest 0 days

Left iliac crest 104
days

Diagnosis

Site (days from
original diagnosis)

Flow (T-cell population of
interest)

np

Large granular lymphocyte-like
cells with condensed chromatin,
inconspicuous nucleoli, eccentric
nuclei, and moderate pale blue
cytoplasm with prominent
azurophilic granules

Positive: CD3c, CD7, CD8, CD45
(b), CD4 equivocal Negative:
CD3, TdT, CD34

nc

Atypical lymphohistiocytic T-cell
Positive: CD2, CD3 (>50%),
inﬁltrate with granulomas; large
CD5, CD7 (f), CD8, CD56,
Positive: CD3, CD3c, CD5, CD7,
mononuclear lymphocytes with
perforin, TIA, CD4 (equivocal)
CD4 (d), CD8 (d), CD45
round to irregular nuclear
Negative: TdT, CD117, CD68,
Negative: TdT, CD34, CD56
contours and moderate eccentric
CD34, CD1a, CD99, granzyme-B,
light blue pale cytoplasm and
CD30, CD57, CD25, ISH EBER
cytoplasmic granules

np

Positive: CD3, CD4/CD8 dual
Positive: TdT, beta F1 Negative: positive, CD2, CD5 (d), CD7, and
TCRc
TDT (d) Negative: CD1a, CD34,
CD117

nc

Small- to medium-sized blast
population comprising 95% of
cells; marrow nearly 100%
cellular

Morphology

IHC (T-cell population of
interest)

Table 1: Patient 1 pathological ﬁndings, by site.
Peripheral blood
Gene
CBC with 100-cell
rearrangements diﬀerential count
(%)∗
18.7
TβA
257
WBCa
TβB
269
Hemoglobinb 10.5
182.9,
MCVc
TβC
92.8
190.84
190.94,
Plateletsa
TcA
211
214.3
TcB
172.9
Lymphocytes 15
Atypical
0
lymphocytes
Blasts
1
TβA
256
WBCa
3.62
126,
TβB
Hemoglobinb 10.8
263.8
TβC 190.63
MCVc
92.8
334
TcA Germline
Plateletsa
TcB
172.4
Lymphocytes 37
Atypical
0
lymphocytes
Blasts
0
np
WBCa
2.44
Hemoglobinb 9.5
MCVc
88.3
104
Plateletsa
Lymphocytes 34.4
Atypical
0
lymphocytes
Blasts
0
TβA
275
WBCa
2.56
126, 258,
TβB
Hemoglobinb 8.7
263.8
182.92,
TβC
MCVc
88.1
190.63
a
TcA 214.13
Platelets
76
TcB 172.48 Lymphocytes 28.9
Atypical
0
lymphocytes
Blasts
0

4
Case Reports in Hematology

cδ PTCL

γδ PTCL

Skin, right arm 125
days

Skin, right ﬂank 189
days

Positive: CD3, CD5, CD4/CD8
dual positive, CD45, CD56
Negative: CD7 (partial loss)

nd

Positive: CD2, CD3, CD5, CD4,
CD8, CD56, TIA, CD99 (d),
granzyme-B, TCRγ Negative:
CD7, TdT, CD34, CD1a

Atypical lymphocytic inﬁltrate
comprised of large pleomorphic
Positive: CD3, CD4, CD8, TCRγ,
with round to irregular nuclear
CD56 Negative: TdT, Beta F1,
contours and ample cytoplasm
CD20
with prominent nucleoli and
elevated N:C ratio

Atypical lymphoid cells

Morphology

Flow (T-cell population of
interest)

IHC (T-cell population of
interest)

Peripheral blood
Gene
CBC with 100-cell
rearrangements diﬀerential count
(%)∗
2.61
np
WBCa
Hemoglobinb 9.8
MCVc
87.9
98
Plateletsa
Lymphocytes 32.2
Atypical
0
lymphocytes
Blasts
0
np
WBCa
9.1
Hemoglobinb 10.9
95.8
MCVc
Plateletsa
58
Lymphocytes 8
Atypical
0
lymphocytes
Blast
0

Note: (b) bright; (d) dim; (f) focal; (s) positive in subset. +/− equivocal; nc, noncontributory; nd, nondiagnostic due to insuﬃcient specimen; np, not performed. aIn k/μL; bin g/dL; cin fL. ∗ Manual diﬀerential used
when available; otherwise, automated impedance counts were utilized.

Diagnosis

Site (days from
original diagnosis)

Table 1: Continued.
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(a)

(b)

(c)

(d)

Figure 5: Patient 2; mediastinal mass with T-cell ALL: (a) H&E, 100x; (b) cytology, 1000x; (c) CD3, 100x; (d) TdT, 100x.

Biopsy of the atrial mass was nondiagnostic showing
myocardial and ﬁbrous tissue. The chest wall (ﬂank) mass was
biopsied showing involvement by PTCL (Figure 6). Pleural
ﬂuid analysis showed involvement by CD3+ large lymphoid
cells with markedly irregular nuclear contours, cytoplasmic
azurophilic granules, lacking TdT and CD7, and showing
positivity for CD8. Clonal TCR β and c gene rearrangements
were detected. Staging bone marrow biopsy showed no evidence of T-ALL.
However, clonal TCR β and c gene rearrangements were
detected with a possible similar peak to that detected in the
pleural eﬀusion sample (Table 2). Shared identical clonal TCR
peaks were not noted between T-ALL and PTCL specimens,
but comparison is limited by the fact that TCR testing was
performed in diﬀerent labs and may have used disparate
primer sets and analysis parameters. The patient later received
2 cycles of ESHAP resulting in partial response. However,
PET scan showed SUV of 11 in the cardiac area. Romidepsin
salvage chemotherapy was administered. The patient continued to have large pleural eﬀusions with respiratory issues
and eventually opted for hospice. She died 4 months after her
presentation with PTCL and 50 months after her original
diagnosis of T-cell ALL, at age 64.

3. Discussion
In both cases, there was relapse as PTCL manifested with
skin involvement and an overt shift from blastic morphology
to “LGL-like” mature T cells with ample cytoplasm and
abundant azurophilic granules. Phenotypically, expression

of immature markers such as TdT was lost in both cases.
Both patients reasonably represent a novel phenomenon
of clonal transformation from T-ALL to PTCL which has
rarely been reported in the literature. In patient 1, there is
clear evidence of a clonal relationship as demonstrated
by identical monoclonal TCR peaks. Also, both PTCL
and T-ALL cases demonstrated the relatively immature
CD4+/CD8+ immunophenotype. HSTLcδ are often
CD4-/CD8-, recapitulating normal cδ T cells, and less
commonly C8+/CD4-is seen. In other cδ PTCLs, CD4+/CD8−
phenotype may be observed perhaps deriving from a subset of
normal cδ T cells that harbor this phenotype [8]. However,
dual CD4+/CD8+ has not been typically reported and is
diﬃcult to explain [16]. A clonal relationship is less clear for
patient 2. However, the genesis of an entirely new PTCL in
a patient with established T-ALL would be unusual indeed.
TCR gene rearrangements cannot be reliably compared between the original T-ALL and PTCL due to their performance
in diﬀering laboratories.
Morphologically, cδ PTCLs are a heterogeneous group.
However, in both our cases we ﬁnd a “LGL-like” morphology with large cells with ample cytoplasm containing
cytoplasmic granules further supporting the notion that
a common phenomenon may be at play in these two cases.
Furthermore, SNP microarray performed on patient 2’s
PTCL showed clonal alterations in 95% of the cells, but
clonal evolution was seen in 41–55% of the cells suggesting
further that this represents a type of transformation. Furthermore, homozygous interstitial deletion 14q32.2 was detected
which houses BCL11B. BCL11B encodes a transcription factor
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(a)

(b)

(c)

Figure 6: Patient 2: (a) ﬂank mass with PTCL, H&E, 100x; (b) ﬂank
mass, TdT immunoperoxidase, 200x; (c) pleural ﬂuid cytospin
cytology, 500x.

necessary for normal T-cell development and has been
implicated in T-ALL pathogenesis [17]. Another line of evidence that supports the idea that these cases may represent
a novel phenomenon is the detection of aberrations occurring
at similar genetic loci in both cases. In patient 1, karyotype

showed 46,XY,add (13) (p11.2) [3]/46,XY[17] in the original
T-ALL. In patient 2, SNP array performed on PTCL containing pleural ﬂuid showed aberration at a similar locus:
13p11.1q24.21(34,474,059–115,670,586)x1-2.
If this truly represents transformation, we must consider
the pathophysiology of such conversion. It may be postulated
that chemotherapy may have forced the original T-ALL cells
to undergo some degree of maturation. However, the disparate chemotherapy regimens in both cases, lack of similar
conversions in other patients treated with these typical chemotherapy regimens, and temporal distance of relapse in
patient 2 (3-4 years) do not support this speculation. More
likely, acquisition of additional mutations in T-cell diﬀerentiation genes may have created a genetic context to allow for
such transdiﬀerentiation. This is supported by SNP array
analysis performed on patient 2’s PTCL showing clonal
evolution. Another possibility is that malignant clones of
T-ALL and PTCL developed separately from a common
precursor sharing an initial transforming event. Subsequently,
T-cell ALL and PTCL could evolve secondary to additional
and separate transforming events.
The transformation into more aggressive disease is a rare
event in T-cell lineage-derived hematologic malignancies
compared to B-cell neoplasms. A patient with cδ-variant of
LGL leukemia who developed aggressive ALL-like disorder
after about 20 years of an indolent course has previously been
reported [16]. Interestingly, cytology of leukemic cells during
aggressive phase of disease did not diﬀer signiﬁcantly from
LGLs assessed during indolent phase of disease. However,
LGLs of the aggressive leukemia revealed very high Ki-67
proliferation index of 80%, and SNP array showed multiple
genetic abnormalities most probably implicated in the
transformation. This report supports our hypothesis that
transformation in T-cell lymphomas/leukemia is a very rare
event and that multiple acquired somatic mutations secondary to therapeutic or environmental factors likely facilitated the transformed phenotype.
Besides the pathophysiology, the clinical and biological
nature of these transformed PTCLs can be considered
challenging. Should these cases be considered “ALL-like”
disorders given their putative clonal derivation from T-ALL
or do they represent a new entity with unique biology? The
second case was considered to be a new entity with unique
biology, hence the aggressive, chemotherapy refractory
course that resulted.
In summary, we report two cases of NHNC PTCL arising
in patients with established diagnoses T-ALL which, in at
least one case, is clonally related. This raises the possibility of
a novel pathologic phenomenon with associated diagnostic
and biological implications.
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Right iliac crest†
1417 days

3/2013

T-cell ALL

Right iliac crest
18 days

Left iliac crest
131 days

T-cell ALL

Pleural ﬂuid 17
days

Normocellular
marrow with
NEM
Normocellular
marrow with
NEM

T-cell ALL

Mediastinal
mass

9/2009

5/2009

Diagnosis

Site (days from
original
diagnosis)

np

Immature lymphoid
blasts
Sheets of lymphoblasts
with high N:C ratio,
immature chromatin,
visible nucleoli, scant
cytoplasm with
occasional cytoplasmic
vacuoles

nc

np

nc

Positive: CD3, CD4, CD8,
TdT, CD99 Negative:
CD79a

nc

np

Positive: TdT (90%)

nc

nc

Positive: CD45 (d),
cyCD3, CD7, CD4, CD8,
TdT (d), CD117, CD10
Negative: CD20, CD34;
loss of surface CD3 and
CD5

Positive: CD2, CD3, CD5
(d), CD7, CD4, CD8,
CD45, CD10 Negative:
CD20, EpCAM,
Cytokeratin

Monotonous population
of immature lymphoid
cells with high N:C ratio,
round to oval nuclei, mild
nuclear irregularity, and
scant cytoplasm

Morphology

IHC (T-cell population of Flow (T-cell population
interest)
of interest)

Table 2: Patient 2 pathological ﬁndings, by site.

TβC
TcA

TβB

TβA

Germline

np

np

WBCa

6.39

0

261.10,
Hemoglobinb 1.7
266.54
188.74
MCVc
90.6
Germline
Plateletsa
165

262.3

nc

13.9
86.2
262
Few

Hemoglobinb
MCVc
Plateletsa
Lymphocytes
Atypical
lymphocytes
Blasts

22

9.94

0

0

18.7

12.8
87.2
209

6.4

WBCa

nc

Germline Hemoglobinb
Germline
MCVc
Germline
Plateletsa
185.23,
Lymphocytes
193.82
Atypical
lymphocytes
Blasts

TβB
TβC
TcA
TcB

Germline

WBCa

Normal

No mitotic
activity

Peripheral blood
CBC with 100-cell
Cytogenetics
diﬀerential count
∗
(%)

TβA

Gene
rearrangements
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3/2013

Diagnosis

Morphology

Left chest wall
mass 1419 days

PTCL, NOS∗∗

np

np

Positive: CD3c, CD8,
CD45 Negative: CD3,
CD7, CD4, TdT, CD117,
CD20, CD34, CD56

IHC (T-cell population of Flow (T-cell population
interest)
of interest)

Skeletal muscle
extensively involved by
a diﬀuse inﬁltrate of large
Positive: CD2, CD3, CD8
lymphoid cells with
(b), ki67 (80%) Negative:
granular chromatin,
CD5, CD7, CD4, TdT,
marked nuclear
CD15, CD20, CD30,
pleomorphism, markedly
CD34, CD56, panirregular nuclear
keratin, PAX5, EBVcontours, occasional
LMP, EBER
horseshoe-shaped nuclei,
and occasional
conspicuous nucleoli

Abundant large lymphoid
cells with condensed
chromatin, markedly
irregular nuclear
contours, frequent
Pleural ﬂuid 1419 PTCL, NOS with horseshoe-shaped nuclei,
days
75% large T-cells occasional binucleation,
inconspicuous nucleoli,
moderate-to-abundant
pale blue cytoplasm, and
cytoplasmic azurophilic
granules

Site (days from
original
diagnosis)

Table 2: Continued.

np

TcB

TcA

TβC

TβB

TβA

TcB

WBCa

nc

0

0

19.6

190

91.5

10.4

6.12

SNP
ARRAY

Peripheral blood
CBC with 100-cell
Cytogenetics
diﬀerential count
∗
(%)
Lymphocytes 19.7
Atypical
0
lymphocytes
Blasts
0

252.79,
Hemoglobinb
272.24
326.3
MCVc
208.3,
Plateletsa
216.77
Germline Lymphocytes
Atypical
lymphocytes
Blasts

259.6
(+/−)

174.32

Gene
rearrangements
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PTCL, NOS

Left ﬂank mass

Large lymphoid cells with
granular chromatin,
marked nuclear
Positive: CD3 (b),
pleomorphism, markedly
granzyme-B Negative:
irregular nuclear
CD5, TdT, CD20, CD30,
contours, occasional
CD34, ALK-1, CD1a,
horseshoe-shaped nuclei,
occasional conspicuous myeloperoxidase, EBER
ISH
nucleoli, moderate pale
eosinophilic cytoplasm,
and abundant cytotoxic
granules

Morphology

Not representative

IHC (T-cell population of Flow (T-cell population
interest)
of interest)

Gene
rearrangements

Peripheral blood
CBC with 100-cell
Cytogenetics
diﬀerential count
∗
(%)

Note: (b) bright; (d) dim; (f) focal; (s) positive in subset; +/− equivocal. NEM, no evidence of malignancy; nc, noncontributory; nd, nondiagnostic due to insuﬃcient specimen; np, not performed. aIn k/μL; bin g/dL;
c
in fL. ∗ Manual diﬀerential used when available; otherwise, automated impedance counts were utilized. †The IHC proﬁle is from a chest wall mass biopsy taken on the same day. This biopsy had a dense atypical
lymphocytic inﬁltrate. ∗∗ Flow photocytometry demonstrated a 5% population of small T-cells. Limited material hindered full evaluation.

Diagnosis

Site (days from
original
diagnosis)

Table 2: Continued.
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